$18.00
-0.59[-3.17%]
At close: Apr 17
$18.00
0[0.00%]
After Hours: 4:00PM EDT
Kura Oncology
(NASDAQ:KURA)Kura Oncology Stock (NASDAQ:KURA), Analyst Ratings, Price Targets, Predictions
Kura Oncology Inc has a consensus price target of $28.63, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Wedbush on March 6, 2024, February 28, 2024, and February 28, 2024. With an average price target of $33.67 between HC Wainwright & Co., HC Wainwright & Co., and Wedbush, there's an implied 87.04% upside for Kura Oncology Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
JMP Securities
Mizuho
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kura Oncology
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | KURA | Buy Now | Kura Oncology | $18.00 | 77.78% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | KURA | Buy Now | Kura Oncology | $18.00 | 77.78% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | KURA | Buy Now | Kura Oncology | $18.00 | 105.56% | Wedbush | Robert Driscoll | → $37 | Reiterates | Outperform → Outperform | Get Alert |
| 01/31/2024 | KURA | Buy Now | Kura Oncology | $18.00 | 77.78% | JMP Securities | Reni Benjamin | $22 → $32 | Maintains | Market Outperform | Get Alert |
| 12/22/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 44.44% | Mizuho | Mara Goldstein | → $26 | Initiates | → Buy | Get Alert |
| 12/08/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 77.78% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 105.56% | Wedbush | Robert Driscoll | $40 → $37 | Maintains | Outperform | Get Alert |
| 10/18/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 122.22% | Wedbush | Robert Driscoll | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 09/07/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 66.67% | Cantor Fitzgerald | Li Watsek | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 72.22% | B of A Securities | Jason Zemansky | → $31 | Initiates | → Buy | Get Alert |
| 07/27/2023 | KURA | Buy Now | Kura Oncology | $18.00 | -41.67% | Scotiabank | George Farmer | → $10.5 | Initiates | → Sector Perform | Get Alert |
| 07/21/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 66.67% | Cantor Fitzgerald | Li Watsek | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 66.67% | Cantor Fitzgerald | Li Watsek | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 22.22% | JMP Securities | Reni Benjamin | → $22 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/12/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 77.78% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 38.89% | Stifel | Bradley Canino | $24 → $25 | Maintains | Buy | Get Alert |
| 05/17/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 72.22% | BTIG | Justin Zelin | → $31 | Initiates | → Buy | Get Alert |
| 05/11/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 44.44% | Credit Suisse | Tiago Fauth | → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 05/11/2023 | KURA | Buy Now | Kura Oncology | $18.00 | 77.78% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Kura Oncology (KURA)?
The latest price target for Kura Oncology (NASDAQ: KURA) was reported by HC Wainwright & Co. on March 6, 2024. The analyst firm set a price target for $32.00 expecting KURA to rise to within 12 months (a possible 77.78% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kura Oncology (KURA)?
The latest analyst rating for Kura Oncology (NASDAQ: KURA) was provided by HC Wainwright & Co., and Kura Oncology reiterated their buy rating.
When was the last upgrade for Kura Oncology (KURA)?
There is no last upgrade for Kura Oncology.
When was the last downgrade for Kura Oncology (KURA)?
There is no last downgrade for Kura Oncology.
When is the next analyst rating going to be posted or updated for Kura Oncology (KURA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Kura Oncology (KURA) correct?
While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Kura Oncology (KURA) is trading at is $18.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.